Severance Hospital is a hospital located in Sinchon-dong, Seodaemun District, South Korea. It is one of the oldest and biggest university hospitals in South Korea. It has 2,437 beds and treats approximately 2,500,000 outpatients and 840,000 inpatients annually.

During the past decade, Severance Hospital conducted 465 clinical trials. In the 10-year time frame, 465 clinical trials started and 102 clinical trials were completed, i.e. on average, 21.9% percent of trials that started reached the finish line to date. In the past 5 years, 193 clinical trials started and 75 clinical trials were completed. i.e. 38.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Severance Hospital" #1 sponsor was "Yonsei University" with 271 trials, followed by "Chong Kun Dang Pharmaceutical" with 37 trials sponsored, "Boehringer Ingelheim" with 24 trials sponsored, "Hoffmann-La Roche" with 22 trials sponsored and "Merck Sharp & Dohme LLC" with 22 trials sponsored. Other sponsors include 414 different institutions and companies that sponsored additional 200 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Severance Hospital" #1 collaborator was "Severance Hospital" with 33 trials as a collaborator, "Asan Medical Center" with 12 trials as a collaborator, "Inje University" with 9 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 9 trials as a collaborator and "CardioVascular Research Foundation, Korea" with 8 trials as a collaborator. Other collaborators include 362 different institutions and companies that were collaborators in the rest 197 trials.

According to Clinical.Site data, the most researched conditions in "Severance Hospital" are "Gastric Cancer" (18 trials), "Healthy" (16 trials), "Hypertension" (16 trials), "Breast Cancer" (15 trials) and "Hepatocellular Carcinoma" (14 trials). Many other conditions were trialed in "Severance Hospital" in a lesser frequency.

Most popular intervention types in "Severance Hospital" are "Drug" (550 trials), "Procedure" (68 trials), "Device" (62 trials), "Biological" (58 trials) and "Other" (45 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (63 trials), "Pembrolizumab" (19 trials), "Paclitaxel" (14 trials), "Bevacizumab" (12 trials) and "Carboplatin" (12 trials). Other intervention names were less common.

The vast majority of trials in "Severance Hospital" are 706 trials for "All" genders, 46 trials for "Female" genders and 39 trials for "Male" genders.

Currently, there are 183 active trials in "Severance Hospital". 7 are not yet recruiting, 105 are recruiting, 68 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 442 completed trials in Severance Hospital, undefined suspended trials, and 39 terminated clinical trials to date.

Out of the total trials that were conducted in Severance Hospital, 115 "Phase 1" clinical trials were conducted, 157 "Phase 2" clinical trials and 170 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 107 trials, and there were also 160 trials that are defined as “Not Applicable".

Severance Hospital has several departments that took part in Clinical trials: "Severance Cardiovascular Hospital, Yonsei University Health System" - 60 trials, "Yonsei Cancer Center at Yonsei University Medical Center" - 52 trials, "Division of Cardiology, Department of Internal Medicine, Severance Hospital" - 4 trials, "Yongdong Severance Hospital" - 4 trials, "Department of Neurology, Severance Hospital, Yonsei University College of Medicine" - 2 trials, "Department of Ophthalmology, Severance Hospital, Yonsei University College of Medicine" - 2 trials, "Severance Hospital; Internal Medicine" - 2 trials